AMRX vs VTRS
AMRX: Amneal Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of a diverse portfolio of generic and specialty medicines. VTRS: Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
Side-by-side fundamentals
| Metric | AMRX | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $19.65 | $17.44 | |
| Market cap | $6.3B | $20.0B | |
| P/E as of 2026-10-08 | 52.68 | n/a | |
| Net margin FY2025, SEC XBRL | +2.4% | -24.6% | AMRX higher |
| Gross margin FY2025, SEC XBRL | +36.9% | +35.1% | AMRX higher |
| Operating margin FY2025, SEC XBRL | +13.1% | -18.6% | AMRX higher |
| ROE FY2025, SEC XBRL | n/a | -23.9% | |
| ROA FY2025, SEC XBRL | +2.0% | -9.5% | AMRX higher |
| Debt / equity as of 2026-09-03 | 136.58 | 0.94 | VTRS lower |
| Revenue growth (YoY) as of 2026-09-03 | +7.6% | +4.4% | AMRX higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | -4.2% | AMRX higher |
| Dividend yield as of 2026-09-02 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | VTRS higher |
| Beta as of 2026-09-03 | 0.81 | 0.75 | |
| 1-year return as of 2026-10-08 close | +87.5% | +74.9% | AMRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.